35.27MMarket Cap-1.84P/E (TTM)
3.410High3.070Low109.64KVolume3.410Open3.420Pre Close350.29KTurnover1.38%Turnover RatioLossP/E (Static)10.78MShares11.99052wk High1.33P/B26.04MFloat Cap2.79052wk Low--Dividend TTM7.96MShs Float24.840Historical High--Div YieldTTM9.94%Amplitude2.380Historical Low3.194Avg Price1Lot Size
Lantern Pharma Stock Forum
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Monday, 9th December at 8:15 am
Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits.
Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers.
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence...
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...
Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
📊⚡️📊
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE
No comment yet